These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 28693926

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Two Clusters of Fluoroquinolone and Clindamycin-Resistant Clostridium difficile PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis.
    Nyc O, Tejkalova R, Kriz Z, Ruzicka F, Kubicek L, Matejkova J, Kuijper E, Krutova M.
    Microb Drug Resist; 2017 Jul; 23(5):609-615. PubMed ID: 27860531
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from hospitals during a 4-year period in China.
    Chen YB, Gu SL, Shen P, Lv T, Fang YH, Tang LL, Li LJ.
    J Med Microbiol; 2018 Jan; 67(1):52-59. PubMed ID: 29160203
    [Abstract] [Full Text] [Related]

  • 6. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.
    Snydman DR, McDermott LA, Jacobus NV, Thorpe C, Stone S, Jenkins SG, Goldstein EJ, Patel R, Forbes BA, Mirrett S, Johnson S, Gerding DN.
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6437-43. PubMed ID: 26239985
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14.
    Knight DR, Giglio S, Huntington PG, Korman TM, Kotsanas D, Moore CV, Paterson DL, Prendergast L, Huber CA, Robson J, Waring L, Wehrhahn MC, Weldhagen GF, Wilson RM, Riley TV.
    J Antimicrob Chemother; 2015 Nov; 70(11):2992-9. PubMed ID: 26221017
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial susceptibilities, resistance mechanisms and molecular characteristics of toxigenic Clostridioides difficile isolates in a large teaching hospital in Chongqing, China.
    Dang Z, Yang B, Xia P, Huang J, Liao J, Li Y, Tang S, Han Q, Luo S, Xia Y.
    J Glob Antimicrob Resist; 2024 Sep; 38():198-204. PubMed ID: 39048055
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of MCB3681 against Clostridium difficile strains.
    Rashid MU, Dalhoff A, Weintraub A, Nord CE.
    Anaerobe; 2014 Aug; 28():216-9. PubMed ID: 25016084
    [Abstract] [Full Text] [Related]

  • 13. A nationwide study of molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile in South Korea.
    Byun JH, Kim H, Kim JL, Kim D, Jeong SH, Shin JH, Kim YA, Shin JH, Shin KS, Uh Y.
    Anaerobe; 2019 Dec; 60():102106. PubMed ID: 31655214
    [Abstract] [Full Text] [Related]

  • 14. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
    Poilane I, Fantinato C, Cruaud P, Collignon A.
    Pathol Biol (Paris); 2008 Dec; 56(7-8):412-6. PubMed ID: 18842360
    [Abstract] [Full Text] [Related]

  • 15. The recognition and characterisation of Finnish Clostridium difficile isolates resembling PCR-ribotype 027.
    Krutova M, Nyc O, Matejkova J, Kuijper EJ, Jalava J, Mentula S.
    J Microbiol Immunol Infect; 2018 Jun; 51(3):344-351. PubMed ID: 28583353
    [Abstract] [Full Text] [Related]

  • 16. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
    Drudy D, Quinn T, O'Mahony R, Kyne L, O'Gaora P, Fanning S.
    J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
    [Abstract] [Full Text] [Related]

  • 17. U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.
    Thorpe CM, McDermott LA, Tran MK, Chang J, Jenkins SG, Goldstein EJC, Patel R, Forbes BA, Johnson S, Gerding DN, Snydman DR.
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085514
    [Abstract] [Full Text] [Related]

  • 18. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014.
    Freeman J, Vernon J, Pilling S, Morris K, Nicholson S, Shearman S, Longshaw C, Wilcox MH, Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes Study Group.
    Clin Microbiol Infect; 2018 Jul; 24(7):724-731. PubMed ID: 29066403
    [Abstract] [Full Text] [Related]

  • 19. Epidemiology of Clostridium difficile infection in hospitalized adults and the first isolation of C. difficile PCR ribotype 027 in central China.
    Zhou Y, Mao L, Yu J, Lin Q, Luo Y, Zhu X, Sun Z.
    BMC Infect Dis; 2019 Mar 07; 19(1):232. PubMed ID: 30845918
    [Abstract] [Full Text] [Related]

  • 20. The tcdA-negative and tcdB-positive Clostridium difficile ST81 clone exhibits a high level of resistance to fluoroquinolones: a multi-centre study in Beijing, China.
    Cheng JW, Liu C, Kudinha T, Xiao M, Fan X, Yang CX, Wei M, Liang GW, Shao DH, Xiong ZJ, Hou X, Yu SY, Wang Y, Yang QW, Su JR, Xu YC.
    Int J Antimicrob Agents; 2020 Jul 07; 56(1):105981. PubMed ID: 32330584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.